从波生坦到马昔腾坦治疗肺动脉高压和成人先天性心脏病：进一步改善？ - Suppr

From bosentan to macitentan for pulmonary arterial hypertension and adult congenital heart disease: Further improvement?

作者信息

Blok Ilja M, van Riel Annelieke C M J, van Dijk Arie P J, Mulder Barbara J M, Bouma Berto J

机构信息

Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands; NLHI - Netherlands Heart Institute, Utrecht, The Netherlands.

Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands.

出版信息

Int J Cardiol. 2017 Jan 15;227:51-52. doi: 10.1016/j.ijcard.2016.11.211. Epub 2016 Nov 9.

DOI:10.1016/j.ijcard.2016.11.211

PMID:27846462

Abstract

摘要

相似文献

From bosentan to macitentan for pulmonary arterial hypertension and adult congenital heart disease: Further improvement?

Int J Cardiol. 2017 Jan 15;227:51-52. doi: 10.1016/j.ijcard.2016.11.211. Epub 2016 Nov 9.

Unilateral absence of a left pulmonary artery: successful therapeutic response to a combination of bosentan and warfarin.

Circ Cardiovasc Imaging. 2009 Nov;2(6):e46-8. doi: 10.1161/CIRCIMAGING.108.825745.

Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease.

Heart. 2007 Aug;93(8):974-6. doi: 10.1136/hrt.2006.089185.

Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down's syndrome.

Am J Cardiol. 2009 May 1;103(9):1309-15. doi: 10.1016/j.amjcard.2009.01.021. Epub 2009 Mar 13.

Tolerability of Switch to Macitentan from Bosentan in Pulmonary Arterial Hypertension.

South Med J. 2017 Mar;110(3):223-228. doi: 10.14423/SMJ.0000000000000607.

Macitentan in Pulmonary Arterial Hypertension Associated with Congenital Heart Defects.

Heart Lung Circ. 2017 Oct;26(10):1006-1007. doi: 10.1016/j.hlc.2017.08.003.

Macitentan for the treatment of pulmonary arterial hypertension.

Expert Rev Respir Med. 2014 Aug;8(4):393-9. doi: 10.1586/17476348.2014.937708. Epub 2014 Jul 6.

Bosentan.

Neonatal Netw. 2011 Jul-Aug;30(4):249-51. doi: 10.1891/0730-0832.30.4.249.

Safety of macitentan in sarcoidosis-associated pulmonary hypertension: a case-series.

Sarcoidosis Vasc Diffuse Lung Dis. 2020;37(1):74-78. doi: 10.36141/svdld.v37i1.9292. Epub 2020 Mar 15.

Macitentan for the treatment of pulmonary arterial hypertension.

Drugs Today (Barc). 2014 Jun;50(6):401-6. doi: 10.1358/dot.2014.50.6.2146837.

引用本文的文献

Macitentan in the Young-Mid-term Outcomes of Patients with Pulmonary Hypertensive Vascular Disease treated in a Pediatric Tertiary Care Center.

Paediatr Drugs. 2023 Jul;25(4):467-481. doi: 10.1007/s40272-023-00573-y. Epub 2023 Jun 3.

Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis.

Front Cardiovasc Med. 2022 Dec 7;9:977110. doi: 10.3389/fcvm.2022.977110. eCollection 2022.

Congenital Heart Disease: The State-of-the-Art on Its Pharmacological Therapeutics.

J Cardiovasc Dev Dis. 2022 Jun 26;9(7):201. doi: 10.3390/jcdd9070201.

Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT).

Pulm Circ. 2022 May 3;12(2):e12083. doi: 10.1002/pul2.12083. eCollection 2022 Apr.

The clinical experience of macitentan in pulmonary hypertension in Indian cohort: 12-month follow-up.

Lung India. 2022 Jan-Feb;39(1):12-15. doi: 10.4103/lungindia.lungindia_671_20.

Macitentan in infants and children with pulmonary hypertensive vascular disease. Feasibility, tolerability and practical issues - a single-centre experience.

Pulm Circ. 2021 Jan 20;11(1):2045894020979503. doi: 10.1177/2045894020979503. eCollection 2021 Jan-Mar.

Safety and efficacy of the endothelin receptor antagonist macitentan in pediatric pulmonary hypertension.

Cardiovasc Diagn Ther. 2020 Oct;10(5):1675-1685. doi: 10.21037/cdt.2020.04.01.

Cost-utility analysis of Macitentan Vs. Bosentan in pulmonary atrial hypertension.

J Family Med Prim Care. 2020 Jul 30;9(7):3634-3638. doi: 10.4103/jfmpc.jfmpc_1166_19. eCollection 2020 Jul.

Bosentan or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension?

Lung. 2019 Dec;197(6):753-760. doi: 10.1007/s00408-019-00274-9. Epub 2019 Oct 3.

Safety and tolerability of macitentan in the management of pulmonary arterial hypertension: an update.

Drug Healthc Patient Saf. 2019 Sep 3;11:71-85. doi: 10.2147/DHPS.S173050. eCollection 2019.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

From bosentan to macitentan for pulmonary arterial hypertension and adult congenital heart disease: Further improvement?

作者信息

Blok Ilja M, van Riel Annelieke C M J, van Dijk Arie P J, Mulder Barbara J M, Bouma Berto J

机构信息

Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands; NLHI - Netherlands Heart Institute, Utrecht, The Netherlands.

Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands.

出版信息

Int J Cardiol. 2017 Jan 15;227:51-52. doi: 10.1016/j.ijcard.2016.11.211. Epub 2016 Nov 9.

DOI:10.1016/j.ijcard.2016.11.211

PMID:27846462

Abstract

摘要

相似文献

From bosentan to macitentan for pulmonary arterial hypertension and adult congenital heart disease: Further improvement?

Int J Cardiol. 2017 Jan 15;227:51-52. doi: 10.1016/j.ijcard.2016.11.211. Epub 2016 Nov 9.

Unilateral absence of a left pulmonary artery: successful therapeutic response to a combination of bosentan and warfarin.

Circ Cardiovasc Imaging. 2009 Nov;2(6):e46-8. doi: 10.1161/CIRCIMAGING.108.825745.

Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease.

Heart. 2007 Aug;93(8):974-6. doi: 10.1136/hrt.2006.089185.

Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down's syndrome.

Am J Cardiol. 2009 May 1;103(9):1309-15. doi: 10.1016/j.amjcard.2009.01.021. Epub 2009 Mar 13.

Tolerability of Switch to Macitentan from Bosentan in Pulmonary Arterial Hypertension.

South Med J. 2017 Mar;110(3):223-228. doi: 10.14423/SMJ.0000000000000607.

Macitentan in Pulmonary Arterial Hypertension Associated with Congenital Heart Defects.

Heart Lung Circ. 2017 Oct;26(10):1006-1007. doi: 10.1016/j.hlc.2017.08.003.

Macitentan for the treatment of pulmonary arterial hypertension.

Expert Rev Respir Med. 2014 Aug;8(4):393-9. doi: 10.1586/17476348.2014.937708. Epub 2014 Jul 6.

Bosentan.

Neonatal Netw. 2011 Jul-Aug;30(4):249-51. doi: 10.1891/0730-0832.30.4.249.

Safety of macitentan in sarcoidosis-associated pulmonary hypertension: a case-series.

Sarcoidosis Vasc Diffuse Lung Dis. 2020;37(1):74-78. doi: 10.36141/svdld.v37i1.9292. Epub 2020 Mar 15.

Macitentan for the treatment of pulmonary arterial hypertension.

Drugs Today (Barc). 2014 Jun;50(6):401-6. doi: 10.1358/dot.2014.50.6.2146837.

引用本文的文献

Macitentan in the Young-Mid-term Outcomes of Patients with Pulmonary Hypertensive Vascular Disease treated in a Pediatric Tertiary Care Center.

Paediatr Drugs. 2023 Jul;25(4):467-481. doi: 10.1007/s40272-023-00573-y. Epub 2023 Jun 3.

Efficacy and safety of switching from bosentan or ambrisentan to macitentan in pulmonary arterial hypertension: A systematic review and meta-analysis.

Front Cardiovasc Med. 2022 Dec 7;9:977110. doi: 10.3389/fcvm.2022.977110. eCollection 2022.

Congenital Heart Disease: The State-of-the-Art on Its Pharmacological Therapeutics.

J Cardiovasc Dev Dis. 2022 Jun 26;9(7):201. doi: 10.3390/jcdd9070201.

Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT).

Pulm Circ. 2022 May 3;12(2):e12083. doi: 10.1002/pul2.12083. eCollection 2022 Apr.

The clinical experience of macitentan in pulmonary hypertension in Indian cohort: 12-month follow-up.

Lung India. 2022 Jan-Feb;39(1):12-15. doi: 10.4103/lungindia.lungindia_671_20.

Macitentan in infants and children with pulmonary hypertensive vascular disease. Feasibility, tolerability and practical issues - a single-centre experience.

Pulm Circ. 2021 Jan 20;11(1):2045894020979503. doi: 10.1177/2045894020979503. eCollection 2021 Jan-Mar.

Safety and efficacy of the endothelin receptor antagonist macitentan in pediatric pulmonary hypertension.

Cardiovasc Diagn Ther. 2020 Oct;10(5):1675-1685. doi: 10.21037/cdt.2020.04.01.

Cost-utility analysis of Macitentan Vs. Bosentan in pulmonary atrial hypertension.

J Family Med Prim Care. 2020 Jul 30;9(7):3634-3638. doi: 10.4103/jfmpc.jfmpc_1166_19. eCollection 2020 Jul.

Bosentan or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension?

Lung. 2019 Dec;197(6):753-760. doi: 10.1007/s00408-019-00274-9. Epub 2019 Oct 3.

Safety and tolerability of macitentan in the management of pulmonary arterial hypertension: an update.

Drug Healthc Patient Saf. 2019 Sep 3;11:71-85. doi: 10.2147/DHPS.S173050. eCollection 2019.

From bosentan to macitentan for pulmonary arterial hypertension and adult congenital heart disease: Further improvement?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

From bosentan to macitentan for pulmonary arterial hypertension and adult congenital heart disease: Further improvement?

作者信息

机构信息

出版信息

相似文献

引用本文的文献